Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Articles, Neurobiology of Disease

Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome

Saurabh K. Garg, Daniel T. Lioy, Hélène Cheval, James C. McGann, John M. Bissonnette, Matthew J. Murtha, Kevin D. Foust, Brian K. Kaspar, Adrian Bird and Gail Mandel
Journal of Neuroscience 21 August 2013, 33 (34) 13612-13620; DOI: https://doi.org/10.1523/JNEUROSCI.1854-13.2013
Saurabh K. Garg
1Vollum Institute and
2Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97239,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel T. Lioy
1Vollum Institute and
2Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97239,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hélène Cheval
3Wellcome Trust Centre for Cell Biology, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR, United Kingdom,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. McGann
1Vollum Institute and
2Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97239,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John M. Bissonnette
4Department of Cell and Developmental Biology and
5Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon 97239,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J. Murtha
7Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, Ohio 43205
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin D. Foust
6Department of Neuroscience, Ohio State University, Columbus, Ohio 43205, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian K. Kaspar
7Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, Ohio 43205
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian Bird
3Wellcome Trust Centre for Cell Biology, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR, United Kingdom,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail Mandel
1Vollum Institute and
2Howard Hughes Medical Institute, Oregon Health and Science University, Portland, Oregon 97239,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    MeCP2 expression is restored throughout the brain after systemic delivery of scAAV9/cre into Mecp2stop/y mice. A, Schematic of the scAAV9/cre viral construct. ITR, inverted terminal repeat; CMV, cytomegalovirus enhancer; CBA, chicken-β-actin promoter; CRE, cre recombinase; BGH, bovine growth hormone. B, Representative sagittal brain sections from 10-week-old WT or virally injected mice. Scale bar, 1 mm. C, Efficiency of virally mediated MeCP2 expression in specified brain regions relative to total DAPI-positive cells (18 sections, n = 3 mice). D, Left: Western blot of MeCP2 protein levels in injected mice. Lane 1, Mecp2+/y; Lane 2, Mecp2stop/y-AAV9/cre. Right: Quantified data of Western blot (n = 3). E, Immunostaining of representative cortical section showing MeCP2 expression in neurons (NeuN+) and astrocytes (GFAP+). Arrow and arrowhead indicate a MeCP2+ astrocyte and neuron, respectively. Scale bar, 10 μm. F, Immunostaining for MeCP2 restoration in Mecp2stop/y mice after scAAV9/cre injection. Cell counts are relative to indicated cell type-specific markers (18 sections, n = 3 mice). G, Western blot (left) of MeCP2 protein levels in different peripheral tissues. Lane 1, Mecp2+/y; Lane 2, Mecp2stop/y-AAV9/cre. Right: Quantified data of Western blot (n = 3). Data are means ± SEM. In C and F, *p < 0.05, **p < 0.01, ***p < 0.001, and NS by one-way ANOVA (Newman–Keuls multiple-comparisons test). Data are means ± SEM.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Systemic delivery of scAAV9/cre into Mecp2stop/y mice rescues abnormal respiration and open field motor activities. A, Experimental paradigm. Mice were analyzed 4–5 weeks after injection. B, Kaplan-Meier survival curve shows significant extension in longevity in scAAV9/cre mice. ***p < 0.001, *p < 0.05, log-rank test. C, Observational scores show stabilization in Mecp2stop/y mice injected with scAAV9/cre (n = 7), scAAV9/Control (n = 5), and noninjected Mecp2+/y mice (n = 12). D, E, Open field activity in scAAV9/cre (n = 3), scAAV9/Control (n = 3), and Mecp2+/y (n = 4) mice. F, Representative plethysmographic recordings from an age-matched Mecp2+/y mouse (top), Mecp2Stop/y mouse before (middle), and 5 weeks post scAAV9/cre injection (bottom). Scale shows time and tidal volume. G, Respiratory pattern returns to normal in scAAV9/cre (n = 6), scAAV9/Control (n = 3), and Mecp2+/y (n = 12) mice. In D, E, and G, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA (Newman–Keuls multiple-comparison test). Data are means ± SEM.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Systemic delivery of scAAV9/cre virus into Mecp2stop/+ mice prevents progression of behavioral abnormalities. A, Experimental paradigm for injection and scoring. B, Observational scores of mice (n = 10) injected with indicated virus or control, noninjected Mecp2+/+ mice (n = 10). Arrow indicates time of behavioral analysis. C, Rotarod analysis on third day of test. D, Platform test for balance. E, Inverted grid test for strength (n = 9). F, Nesting ability (n = 9) with scoring guide at right. G, Novel object recognition analysis showing discrimination index on last day of test (n = 9). H, Brain weights analyzed 40 weeks after injection or in age-matched noninjected mice (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001, NS by one-way ANOVA (Newman–Keuls multiple-comparison test for C and H) and one-way ANOVA (Dunn's multiple-comparison test for D–G). Data are means ± SEM.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Direct brain injections of scAAV9/cre virus into Mecp2stop mice result in predominantly neuronal-specific MeCP2 expression and a mild improvement of behavioral phenotypes. A, Schematic showing site of injections (*). B, Experimental paradigm for males. C, Immunostaining of representative striatal section from a Mecp2stop/y mouse injected with scAAV9/cre shows MeCP2 expression in neurons (NeuN+). Scale bar, 200 μm. D–G, Quantification of immunostaining data (n = 3). Data are means ± SEM. Cell counts are relative to total DAPI-positive cells (D), total NeuN-positive cells (E), total NeuN-negative cells (F), and total MeCP2-positive cells (G). H, Experimental paradigm for females. I, Observational scores for female Mecp2Stop/+ mice injected with scAAV9/cre (n = 5), scAAV9/Control (n = 5), and noninjected Mecp2+/+ mice (n = 12).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Systemic injection of Mecp2Bnull/y mice with scAAV9/MeCP2 virus results in MeCP2 expression in different cell types in brain. A, Schematic of scAAV9/MeCP2 vector. Mouse Mecp2-e1 is cloned downstream of 730 bp fragment of Mecp2 promoter. Other abbreviations are as noted in the legend to Figure 1. B, Experimental paradigm. C, Immunostaining of MeCP2 expression in different brain regions. Cell counts are relative to total DAPI-positive cells (36 sections, n = 2 mice). D, Expression of MeCP2 in neurons and non-neuronal cells varies with brain region. Cell counts are relative to indicated cell-specific marker (12 sections, n = 2 mice). *p < 0.05, **p < 0.01, ***p < 0.001, NS by one-way ANOVA (Newman–Keuls multiple-comparison test). Data are means ± SEM. E, Western blot of MeCP2 protein in different brain regions. Lane 1, Mecp2+/y; Lane 2, Mecp2Bnull/y; and Lane 3, Mecp2Bnull/y-AAV9/MeCP2.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    MeCP2 expressed from virus binds to DNA, restores normal neuronal somal size, and improves survival. A, Ectopic MeCP2 localizes to DAPI+ heterochromatin puncta in Mecp2Bnull/y-scAAV9/MeCP2–injected mice. Shown is colocalization of DAPI and MeCP2 in olfactory neuron (top), CA3 pyramidal neuron (middle), and dentate gyrus astrocyte (bottom). Pearson's correlation coefficient = 0.943, 0.932, and 0.985, respectively. Scale bar, 5 μm. B, Image (left) shows representative MeCP2-positive (arrow) and MeCP2-negative (arrowhead) CA3 pyramidal neurons. Scale bar, 10 μm. Average somal diameters (right) of MeCP2-positive (purple) and MeCP2-negative (red) CA3 pyramidal neurons and olfactory bulb mitral cells from Mecp2Bnull/y-scAAV9/MeCP2–injected mice (n = 2). Also shown are measurements from WT mice (black bars; n = 2). The number of cells analyzed is indicated above each bar. ***p < 0.001 by one-way ANOVA (Newman–Keuls multiple-comparison test). Data are means ± SEM. C, Kaplan-Meier survival curve. D, Observational scores. Mecp2Bnull/y-scAAV9/MeCP2 (n = 5), Mecp2Bnull/y-AAV9/Control (n = 6), and Mecp2+/y (n = 6). Data are means ± SEM. E, Field pixel intensities of MeCP2-Cy3 immunofluorescence measured from brainstem sections of Mecp2+/y and Mecp2Bnull/y-scAAV9/MeCP2 mice. Traces represent pixel intensities from individual fields and each field is indicated by a differently colored trace, n = 2 mice per genotype, 5 fields per mouse.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Systemic delivery of scAAV9/MeCP2 virus into Mecp2Bnull/+ mice prevents progression of aberrant behaviors. A, Experimental paradigm. Mice were analyzed 5 months after injection. B, Field pixel intensities of MeCP2-Cy3 immunofluorescence measured from brainstem sections of WT and scAAV9/MeCP2–injected females. Traces represent pixel intensities from individual fields and each field is indicated by a differently colored trace. n = 2 mice per genotype, 5 fields per mouse. C, Observational scores of Mecp2Bnull/+ mice injected with scAAV9/MeCP2 (n = 8), scAAV9/Control (n = 5), and noninjected (Mecp2+/+) mice (n = 8). Arrow indicates time of behavioral analysis. D, Rotarod activity on third day of test. E, Inverted grid test. F, Platform test for scAAV9/MeCP2 (n = 8), scAAV9/Control (n = 5), and Mecp2+/+ (n = 8) mice. G, Nesting ability of scAAV9/MeCP2 (n = 8), scAAV9/Control (n = 5), and Mecp2+/+ (n = 8) mice. *p < 0.05, **p < 0.01, ***p < 0.001, NS by one-way ANOVA (Newman–Keuls multiple-comparison test for D and one-way ANOVA with Dunn's multiple-comparison test for E–G). Data are means ± SEM.

Back to top

In this issue

The Journal of Neuroscience: 33 (34)
Journal of Neuroscience
Vol. 33, Issue 34
21 Aug 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome
Saurabh K. Garg, Daniel T. Lioy, Hélène Cheval, James C. McGann, John M. Bissonnette, Matthew J. Murtha, Kevin D. Foust, Brian K. Kaspar, Adrian Bird, Gail Mandel
Journal of Neuroscience 21 August 2013, 33 (34) 13612-13620; DOI: 10.1523/JNEUROSCI.1854-13.2013

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome
Saurabh K. Garg, Daniel T. Lioy, Hélène Cheval, James C. McGann, John M. Bissonnette, Matthew J. Murtha, Kevin D. Foust, Brian K. Kaspar, Adrian Bird, Gail Mandel
Journal of Neuroscience 21 August 2013, 33 (34) 13612-13620; DOI: 10.1523/JNEUROSCI.1854-13.2013
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Choice Behavior Guided by Learned, But Not Innate, Taste Aversion Recruits the Orbitofrontal Cortex
  • Maturation of Spontaneous Firing Properties after Hearing Onset in Rat Auditory Nerve Fibers: Spontaneous Rates, Refractoriness, and Interfiber Correlations
  • Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration
Show more Articles

Neurobiology of Disease

  • Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation
  • Prolactin-Releasing Peptide Contributes to Stress-Related Mood Disorders and Inhibits Sleep/Mood Regulatory Melanin-Concentrating Hormone Neurons in Rats
  • mTORC2 Inhibition Improves Morphological Effects of PTEN Loss, But Does Not Correct Synaptic Dysfunction or Prevent Seizures
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.